Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294683 | 1.00 | CCR1 (0.58) | CCR1CHRM3CHRM2CHRM1ATM | |
| SCHEMBL17294626 | 1.00 | CCR1 (0.58) | CCR1CHRM3CHRM2CHRM1ATM | |
| SCHEMBL17294700 | 0.80 | CHRM2 (0.57) | CCR1CHRM3CHRM2CHRM1 | |
| SCHEMBL17301739 | 0.80 | CHRM2 (0.57) | CCR1CHRM3CHRM2CHRM1 | |
| SCHEMBL17294698 | 0.80 | CHRM2 (0.57) | CCR1CHRM3CHRM2CHRM1 | |
| SCHEMBL4356360 | 0.78 | CTSL (0.57) | CHRM1CHEK1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL10210847 | 0.78 | CTSL (0.57) | CHRM1CHEK1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24672004 | 0.76 | CCR1 (0.44) | CCR1CHRM3CHRM2CHRM1ATM | |
| SCHEMBL10211615 | 0.76 | EPHX2 (0.64) | — | |
| SCHEMBL10210791 | 0.76 | EPHX1 (0.64) | ATMCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | claimed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | claimed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | claimed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | claimed |
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| CN-106659697-B | Compounds as antituberculosis agents | 斯菲叶尔制药私有公司 | 2022-03-29 | — | — | CN | disclosed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-10100012-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2018-10-16 | — | — | US | disclosed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100012-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | CCR1 1514/4885CHRM3 2760/4885CHRM2 2407/4885 |
| US-10207993-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | CCR1 1514/4885CHRM3 2760/4885CHRM2 2407/4885 |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | CCR1 1727/4885CHRM3 2635/4885CHRM2 2458/4885 |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | CCR1 1727/4885CHRM3 2635/4885CHRM2 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.